Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors
Open Access
- 22 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 29 (22), 3185-3195
- https://doi.org/10.1038/onc.2010.75
Abstract
Novel therapeutic agents combined with innovative modes of delivery and non-invasive imaging of drug delivery, pharmacokinetics and efficacy are crucial in developing effective clinical anticancer therapies. In this study, we have created and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that comprises unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC) to provide sustained on-site delivery of secretable aaTSP-1 to tumor-vasculature. We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microvascular endothelial cells co-cultured with established glioma cells and CD133+ glioma-initiating cells. Using human glioma cells and hNSC engineered with different combinations of fluorescent and bioluminescent marker proteins and employing multi-modality imaging techniques, we show that aaTSP-1 targets the vascular-component of gliomas and a single administration of hNSC-aaTSP-1 markedly reduces tumor vessel-density that results in inhibition of tumor-progression and increased survival in mice bearing highly malignant human gliomas. We also show that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice. This study provides a platform for accelerated development of future cell-based therapies for cancer.This publication has 37 references indexed in Scilit:
- Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Bimodal Viral Vectors andIn VivoImaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma ModelJournal of Neuroscience, 2008
- VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospectsTrends in Molecular Medicine, 2007
- Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer modelCancer Letters, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combinationEuropean Journal of Cancer, 2006
- Glioma therapy and real‐time imaging of neural precursor cell migration and tumor regressionAnnals of Neurology, 2004
- Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growthNeuron Glia Biology, 2004
- Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivoOncogene, 2003
- The Hallmarks of CancerCell, 2000